Meanwhile, accumulating evidence has demonstrated that the menin–MLL complex participates in the tumorigenesis of prostate cancer [17,28]; subsequently, several reports studied the effect of menin–MLL inhibitors on prostate cancer (PCa), such as MI-503 [5,28,29]. This evidence concerns the gene KMT2A and prostate carcinoma.